Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Metronomic Chemotherapy

  • Eddy PasquierEmail author
  • Nicolas André
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_6973-2



Metronomic chemotherapy was originally defined as the chronic administration of chemotherapeutic drugs at relatively low, minimally toxic doses and with no prolonged drug-free breaks. It is by essence opposed to conventional chemotherapy, which is based on the administration of chemotherapy drugs slightly below or at the maximum-tolerated dose every 2 or 3 weeks.



Given the high sensitivity of vascular endothelial cells to chemotherapeutic drugs, it was hypothesized that more frequent administration of these drugs at lower doses would result in a potent inhibition of tumor angiogenesis and would prevent the rapid vascular rebound that often occurs during prolonged drug-free breaks following conventional chemotherapy. This gave rise to the concept of anti-angiogenic chemotherapy, which was then...


Chemotherapy Angiogenesis Resistance Immunity 
This is a preview of subscription content, log in to check access.


  1. André N, Banavali S, Snihur Y, Pasquier E (2013) Has the time come for metronomics in low-income and middle-income countries? Lancet Oncol 14:e239–e248CrossRefPubMedGoogle Scholar
  2. André N, Carré M, Pasquier E (2014) Metronomics: towards personalized chemotherapy? Nat Rev Clin Oncol 11:413–431CrossRefPubMedGoogle Scholar
  3. Browder T, Butterfield CE, Kräling BM, Shi B, Marshall B, O’Reilly MS, Folkman J (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878–1886PubMedGoogle Scholar
  4. Hanahan D, Bergers G, Bergsland E (2000) Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Investig 105:1045–1047CrossRefPubMedPubMedCentralGoogle Scholar
  5. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS (2000) Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Investig 105:R15–R24CrossRefPubMedPubMedCentralGoogle Scholar

Further Reading

  1. (2012) Maintenance chemotherapy. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin, p 2137. doi:10.1007/978-3-642-16483-5_6974Google Scholar
  2. (2012) Maximum tolerated dose. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin, p 2188. doi:10.1007/978-3-642-16483-5_3567Google Scholar
  3. (2012) Palliative care. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer Berlin Heidelberg, p 2759. doi:10.1007/978-3-642-16483-5_4351Google Scholar
  4. (2012) Tumor-associated angiogenesis. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin, p 3807. doi:10.1007/978-3-642-16483-5_6016Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Centre for Research in Oncobiology and Oncopharmacology, INSERM U911MarseilleFrance
  2. 2.Metronomics Global Health InitiativeMarseilleFrance
  3. 3.Children’s Cancer InstituteRandwickAustralia
  4. 4.Department of Pediatric Hematology and OncologyLa Timone Children’s HospitalMarseilleFrance